NEXTrackerの空売り状況は、投資家がNEXTrackerの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

NEXTracker (NASDAQ:NXT) 株価情報, 空売り情報

NEXTracker

Nextracker (and its subsidiaries) is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and distributed generation solar projects around the world. Nextracker's products enable solar panels in utility-scale power plants to follow the sun's movement across the sky and optimize plant performance. Nextracker has operations in the United States, Mexico, Spain and other countries in Europe, India, Australia, the Middle East, Africa, and Brazil.

NEXTracker Inc

NEXT BIOMETRICS GRP ORD by Next Biometrics Group AS

Next Biometrics Group ASA

NextCure Inc

Investment Managers Series Trust II AXS Green Alpha ETF

NEXTRACTION ENERGY CORP by Nextraction Energy Corp.

Nextraction Energy Corp

First Trust Indxx NextG ETF

NXT NUTRITIONALS HLDG INC by NXT Nutritionals Holdings, Inc.

NXT Nutritionals Holdings Inc

Simplify Exchange Traded Funds Simplify Next Intangible Core Index ETF

Next10 Inc

Nexstim Oyj

NEXTPLAY TECHS INC by NextPlay Technologies, Inc.

NextPlay Technologies Inc

Next Technology Holding Inc. - Ordinary Shares

Next Technology Holding Inc

Lifeist Wellness Inc

FIRST TRUST INDXX NEXTG UCITS ETF

Simplify Exchange Traded Funds Simplify Next Intangible Value Index ETF

NEXITY FINANCIAL CORP by Nexity Financial Corp.

Nexity Financial Corp

Barclays analyst Alex Scott maintains Sun Life Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SLF#TSX">SLF</a>) with a Equal-Weight and raises the price target from C$76 to C$79.

News

Price Target

Analyst Ratings

TSX:SLF

Barclays Maintains Equal-Weight on Sun Life Financial, Raises Price Target to C$79

Bionomics Ltd &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares are trading higher by 177% to 53 cents Tuesday morning after the company announced it <a href="https://www.benzinga.com/pressreleases/24/11/g41727839/bionomics-receives-milestone-payment-of-aus-1m-from-carina-biotech-for-bnc101-partnered-legacy-onc">received a milestone payment</a> of AUD$1 million from Carina Biotech related to their partnered oncology program, BNC101.
What To Know: This payment aligns with their 2020 exclusive license agreement for BNC101, a monoclonal antibody targeting LGR5, a cancer stem cell antigen. 
Carina Biotech is developing an LGR5-targeted CAR-T therapy, CNA3103, for metastatic colorectal cancer, and Bionomics could earn up to AUD$118 million in further development, regulatory and commercial milestone payments if the therapy is fully developed and marketed.
Additionally, Bionomics is set to earn royalties on net sales and may receive a share of sublicensing revenue. Bionomics' CEO highlighted this payment as a testament to their research strength and noted the progress of their strategic partnership with Merck for an Alzheimer&#8217;s therapy, which could soon yield additional milestone payments.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/41740288/us-stocks-set-for-cautious-start-as-investors-brace-for-volatility-on-election-day-expert-points-to">US Stocks Set For Cautious Start As Investors Brace For Volatility On Election Day: Expert Points To &#8216;Pretty Well Overall&#8217; Historical Performance</a>
<h2 class="wp-block-heading">How To Buy BNOX Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Bionomics&#8217; case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, BNOX has a 52-week high of $2.84 and a 52-week low of $0.18.

BNOX

Why Bionomics (BNOX) Stock Is Up 100% Today

REQORSA Modulates In Vivo Immune Responses Against Cancers
AUSTIN, Texas, Nov. 5, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4294293-1&amp;h=152405195&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc.">Genprex, Inc.</a> ("Genprex" or the "Company") (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gnpx#NASDAQ">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators at Meharry Medical College will present a poster detailing positive preclinical data from a study of the Company's lead drug candidate, Reqorsa&#xAE; Gene Therapy (quaratusugene ozeplasmid)&nbsp;evaluating TUSC2's role in modulating immune responses in cancer. The poster will be presented at the 39th Annual Society for Immunotherapy of Cancer Meeting being held November 6-10, 2024 in Houston, Texas.

Biotech

Penny Stocks

General

GNPX

Genprex Collaborators Present Preclinical Data On Reqorsa Gene Therapy At The Society For Immunotherapy Of Cancer 2024 Annual Meeting; REQORSA Modulates In Vivo Immune Responses Against Cancers

Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) has outperformed the market over the past 5 years by 5.75% on an annualized basis producing an average annual return of 18.82%. Currently, Brinker International has a market capitalization of $4.85 billion. 
Buying $1000 In EAT: If an investor had bought $1000 of EAT stock 5 years ago, it would be worth $2,342.45 today based on a price of $108.40 for EAT at the time of writing.
<h3>Brinker International's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730817033_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today

CRKN

Crown Suspends Equity Line of Credit Agreement With Liqueous LP

Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) has outperformed the market over the past 15 years by 2.58% on an annualized basis producing an average annual return of 14.16%. Currently, Union Pacific has a market capitalization of $139.38 billion. 
Buying $100 In UNP: If an investor had bought $100 of UNP stock 15 years ago, it would be worth $740.21 today based on a price of $229.91 for UNP at the time of writing.
<h3>Union Pacific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730817028_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 15 Years Ago Would Be Worth $700 Today

Nuwellis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) ("Nuwellis" or the "Company"), a commercial-stage medical device company committed to transforming the lives of people with fluid overload, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants issued by the Company on April 30, 2024 (collectively, the "Existing Warrants") to purchase up to an aggregate of 1,832,517 shares of the Company's common stock at their current exercise price of $2.10 per share for total gross proceeds of approximately $3.8 million, prior to deducting inducement agent fees and estimated offering expenses. An additional $1.3 million of gross proceeds was received through the exercise of warrants over the last week in accordance with their original terms.
Ladenburg Thalmann &amp; Co. Inc. acted as the exclusive warrant inducement agent for the exercise of the Existing Warrants.
In consideration for the immediate exercise of the Existing Warrants, the Company will issue Series I common stock purchase warrants (the "Series I Warrants") and Series II common stock purchase warrants (the "Series II Warrants") to purchase up to an aggregate of 3,665,034 shares of common stock. The Series I Warrants will have an exercise price of $1.94, will be exercisable six (6) months from the date of issuance, and will have a term of five (5) years from the date of exercisability. The Series II Warrants will have an exercise price of $1.94, will be exercisable six (6) months from the date of issuance, and will have a term of two (2) years from the date of exercisability. The Series I Warrants and Series II Warrants are fixed priced and do not contain any variable pricing features.
The Series I Warrants and Series II Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933 (the "Securities Act"), and, along with the shares of common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the "SEC") or an applicable exemption from such registration requirements.&nbsp; The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the Series I Warrants and Series II Warrants.

Offerings

NUWE

Nuwellis Announces Exercise Of Warrants For $5.1M Of Gross Proceeds

Barclays analyst Brandt Montour maintains Wynn Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) with a Overweight and lowers the price target from $125 to $119.

WYNN

Barclays Maintains Overweight on Wynn Resorts, Lowers Price Target to $119

<ul>
<li>Tevogen Bio begins pre-clinical effort for TVGN 920, signaling the start of its oncology treatment pipeline.</li>
<li>Tevogen Bio created a data set containing known proteins in the HPV genome to identify targets, accelerating the pre-clinical process.</li>
<li>5.5 million women per year have HPV 16/18; of these 200,000 women per year are diagnosed with high grade dysplasia.</li>
</ul>
WARREN, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=25EKK8KKg8fWa8WgKgjIJIFco_i1oqLlmbjUnyWXT5iNb9JBKkEdmsGmc5z909wZYXpUbPo70t3zgkjZ4RPLbA==">Tevogen Bio</a> ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, recently announced its Artificial Intelligence effort, Tevogen.AI, had partnered with Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), the world's leading AI company.
Using Microsoft's suite of advanced tools, Tevogen Bio is proactively investigating potential treatments for HPV to create a portfolio of oncology products. The company has developed a dataset of proteins from the HPV genome and is identifying cytotoxic T cell (CTL) targets to choose for a clinical trial for TVGN 920, its first oncology product. Through Tevogen's proprietary ExacTcell&#x2122; technology, where CTLs are trained to detect specific targets and then expanded, the company aims to be prepared to deliver an HPV-specific CTL treatment.

MSFT

TVGN

Tevogen Bio Leverages Microsoft Partnership To Deliver Machine Learning Based Target Identification To Address HPV, Advancing TVGN 920

Barclays analyst Julian Mitchell maintains Vontier (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNT#NYSE">VNT</a>) with a Overweight and raises the price target from $44 to $46.

Barclays Maintains Overweight on Vontier, Raises Price Target to $46

The result of the combined effort of the two companies will be LiveWire's first electric maxi-scooter planned to launch in 1H 2026

LVWR

LiveWire & KYMCO Expand Partnership Resulting In First Electric Max-Scooter Planned To Launch In 1H 2026

Global

INTC

"Intel CEO Pat Gelsinger Paid A Brief Visit To Taiwan In Early November To Meet With TSMC Chairman C. C. Wei At The Hsinchu Science Park To Finalize 2nm And 3nm Production Capacity For 2024 And 2025, According To Industry Sources" - DigiTimes Alert

Barclays analyst Eddie Kim maintains Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) with a Overweight and lowers the price target from $61 to $59.

Barclays Maintains Overweight on Valaris, Lowers Price Target to $59

Rigel Resource Acquisition Corp (the "Company" or "Rigel") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRAC#NYSE">RRAC</a>) announced that it received a notification letter from the New York Stock Exchange ("NYSE") on November 4, 2024, stating that it would suspend the listing of the Company's (i) Class A ordinary shares, par value $0.0001 per share (the "Class A Ordinary Shares"), (ii) warrants, each exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share (the "Warrants") and (iii) units, each consisting of one Class A Ordinary Share and one-half of one Warrant (the "Units" and, collectively with the Class A Ordinary Shares and the Warrants, the "Securities") from the NYSE before market open on November 5, 2024 and commence delisting proceedings with respect to such Securities.
The NYSE determined to take these actions because Sections 102.06e and 802.01B of the NYSE's Listed Company Manual do not permit a special purpose acquisition company, such as the Company, to remain listed for more than three years after the company's initial public offering without completing an initial business combination.
Following the suspension of trading on the NYSE, the Securities are expected to trade on the OTC Pink Market.

RRAC

Rigel Resource Acquisition Corp Announces Receipt Of NYSE Delisting Notice, States That It Would Suspend The Listing Of The Co's Class A Ordinary Shares, Warrants, Each Exercisable For One Class A Ordinary Share At An Exercise Price Of $11.50 Per Share

- CRG-023 is a CD19-, CD20-, CD22-targeting tri-specific CAR T product candidate designed with the goal of providing more patients with a broad range of B-cell malignancies with durable responses by addressing several known causes of relapse, resulting in a potential best-in-class CAR T-cell therapy -
- First of its kind, tri-cistronic CAR T to express three independent CARs from a single vector, with each CAR having a distinct co-stimulatory domain –
- Data demonstrated sustained anti-tumor activity and a lack of functional exhaustion during repeated challenge from tumor cells, preservation of T cell memory phenotype relative to controls, sustained tumor clearance when only a single antigen is expressed, and robust in vivo, anti-lymphoma activity at low CAR T dose levels -
- Abstract will be presented during poster presentation at ASH, Saturday, December 7, 2024; 5:30 PM - 7:30 PM PST -

Events

CRGX

CARGO Therapeutics Announces ASH 2024 Abstract On CRG-023

Deutsche Bank analyst Carlo Santarelli maintains Wynn Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) with a Buy and lowers the price target from $122 to $118.

Deutsche Bank Maintains Buy on Wynn Resorts, Lowers Price Target to $118

Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) reported worse-than-expected third-quarter financial results and issued FY24 adjusted EPS guidance below <a href="https://www.benzinga.com/quote/MAR/earnings">estimates on Monday</a>.
The company reported a third-quarter adjusted EPS of $2.26, missing the street view of $2.31. Quarterly sales of $6.26 billion marginally missed the analyst consensus of $6.27 billion.
CEO Anthony Capuano highlighted Marriott&#8217;s strong quarter, noting solid net room and fee growth, active development, and a 3% rise in global RevPAR. He added that third-quarter international RevPAR increased by 5.4%, driven by substantial growth in APEC and EMEA regions, steady domestic and cross-border demand, and strong ADR gains.
Marriott expects fourth-quarter 2024 gross fee revenues to range between $1.29 billion and $1.31 billion, with adjusted EPS projected to be $2.31-$2.39, compared to a $2.31 estimate.
Marriott projects full-year 2024 adjusted EPS of $9.19-$9.27 (prior $9.23-$9.40), compared to the $9.36 estimate, with gross fee revenues of $5.126 billion-$5.146 billion (prior $5.13 billion-$5.18 billion).
Marriott shares fell 1.6% to close at $256.43 on Monday.
These analysts made changes to their price targets on Marriott following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5967569b988ca8000127b8de/michael-bellisario">Baird analyst Michael Bellisario</a> maintained Marriott Intl with a Neutral and raised the price target from $258 to $264.</li>
<li>Barclays analyst Brandt Montour maintained the stock with an Equal-Weight and raised the price target from $240 to $249.</li>
</ul>
Considering buying MAR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="544" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05092444/image-32-1024x544.png" alt="" class="wp-image-630414" style="width:646px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05092444/image-32-1024x544.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05092444/image-32-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05092444/image-32-768x408.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05092444/image-32.png 1217w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41743859/top-3-consumer-stocks-that-may-keep-you-up-at-night-this-quarter">Top 3 Consumer Stocks That May Keep You Up At Night This Quarter</a></li>
</ul>

Earnings

Markets

Marriott Analysts Boost Their Forecasts After Q3 Earnings

Barclays analyst Raimo Lenschow maintains Teradata (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>) with a Underweight and lowers the price target from $30 to $29.

Barclays Maintains Underweight on Teradata, Lowers Price Target to $29

Palantir Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares are making new highs on Tuesday after the company reported strong quarterly results driven by <a href="https://www.benzinga.com/news/earnings/24/11/41730179/palantir-q3-earnings-revenue-beat-eps-beat-customers-up-39-raises-guidance-results-driven-by-unrele">&#8220;unrelenting&#8221; AI demand</a>. 
<ul>
<li>Q3 Revenue: $725.52 million, beating the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $701.13 million</li>
</ul>
<ul>
<li>Q3 EPS: 6 cents, versus estimates of 4 cents</li>
</ul>
Palantir reported 30% year-over-year revenue growth in the quarter propelled by continued strength in the U.S. The company said U.S. revenue grew 44% year-over-year as U.S. Commercial revenue jumped 54% and U.S. Government revenue climbed 40% year-over-year.
The company beat analyst estimates on the top and bottom lines for the fifth consecutive quarter as margins expanded for the eighth straight quarter, and the company guided for continued GAAP operating income and net income in each quarter this year.
Customer count grew 39% year-over-year and 6% on a quarter-over-quarter basis. The company said it closed 104 deals worth over $1 million during the quarter.
&#8220;The growth of our business is accelerating, and our financial performance is exceeding expectations as we meet an unwavering demand for the most advanced artificial intelligence technologies from our U.S. government and commercial customers," Alex Karp, co-founder and CEO of Palantir, said in a letter to shareholders.
Check This Out: <a href="https://www.benzinga.com/news/24/11/41738657/palantir-ceo-alex-karp-warns-europe-risks-doom-without-ai">Palantir CEO Alex Karp Warns Europe Risks Doom Without AI</a>
Guidance: Palantir sees fourth-quarter revenue in the range of $767 million to $771 million, versus estimates of $741.44 million. The company also raised full-year guidance across its key metrics.
Palantir now expects full-year revenue in the range of $2.805 billion to $2.809 billion versus estimates of $2.759 billion, and full-year U.S. commercial revenue in excess of $687 million, representing growth of at least 50%. The company now expects adjusted free cash flow to be in excess of $1 billion for the year.
"We absolutely eviscerated this quarter, driven by unrelenting AI demand that won't slow down. This is a U.S.-driven AI revolution that has taken full hold. The world will be divided between AI haves and have-nots. At Palantir, we plan to power the winners,"&nbsp;Karp said.
Following the print, Wedbush analyst&nbsp;Dan Ives&nbsp;maintained an <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41732827/messi-of-ai-wall-street-analyst-gushes-over-robust-earnings-from-palantir">Outperform rating</a> on the stock noting that Palantir delivered &#8220;another robust quarter featuring beats across the board.&#8221;
"Despite the skeptics honing in on valuation for the past year, this was a major quarter to prove that PLTR&#8217;s partner ecosystem expansion and AIP bootcamps hit another gear," Ives said.
PLTR Price Action: <a href="https://www.benzinga.com/quote/PLTR" target="_blank" rel="noreferrer noopener">Palantir shares </a>were up 15.7% at $47.93 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41734887/cathie-woods-latest-shake-up-dumps-palantir-and-jack-dorseys-block-along-with-tesla-buys-amazon-">Cathie Wood&#8217;s Latest Shake-up: Dumps Palantir And Jack Dorsey&#8217;s Block Along With Tesla, Buys Amazon And Meta</a></li>
</ul>
Photo: <a href="https://www.flickr.com/photos/doctorow/" target="_blank" rel="noreferrer noopener">Cory Doctorow</a>&nbsp;from Flickr.

Movers

PLTR

Palantir Stock Is Hitting New Highs: What's Going On?

Barclays analyst Nicholas Campanella maintains Public Service Enterprise (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEG#NYSE">PEG</a>) with a Overweight and lowers the price target from $98 to $88.

Barclays Maintains Overweight on Public Service Enterprise, Lowers Price Target to $88

Solar stocks trading higher following last night's presidential debate

Fidelity Select Utilities Portfolio Q2 2024 Review

American Century Small Cap Growth Fund Q2 2024 Commentary

Acuity Brands: Inching Closer To An Upgrade As Earnings Near

Array: Not Yet In Fashion, But 3 Reasons To Consider A Nibble Now (Rating Upgrade)

Wolfe's tax loss selling stocks within industrials, tech, materials

Nextracker: Market Leadership And Growth Prospects Make It A Buy

The Bottom Fishing Club - Array Technologies: Solar Industry Turnaround Possible After Election

Nextracker Non-GAAP EPS of $0.97 beats by $0.36, revenue of $636M beats by $22.23M

Nextracker Inc. (NXT) Q2 2025 Earnings Call Transcript

ADMA

AEMB

AGCO

AHYB

ALGM

ARRY

ATKR

AZEK

BILL

BRZE

CFLT

CLVT

CNXC

CSIQ

ENPH

EPAM

ESGA

ESGY

FBCG

FBCV

FBND

FBTC

FCEL

FCLD

FCOM

FCOR

FCPI

FDHY

FDIG

FDIS

FDLO

FDMO

FDRR

FDVV

FENY

FETH

FHLC

FIDI

FIDU

FIVN

FLNC

FMAG

FMAT

FMET

FNCL

FQAL

FREL

FRSH

FSLR

FSMD

FSTA

FTAI

FTAIM

FTAIN

FTAIO

FTEC

FUSI

FUTY

FVAL

GNRC

GTLB

GTLS

GWRE

IPGP

KORP

LSCC

MAXN

NOVA

NTRA

OLLI

ONEQ

PATH

PAYC

POWI

PYCR

QCON

QGRO

QINT

QLYS

QPFF

QTWO

SDSI

SEDG

SHLS

SIRI

SITE

SMCI

SNAP

SNOW

SREA

TAXF

TEAM

VALQ

WOLF

XPRO

Press Releases

Nextracker to Announce First Quarter Fiscal 2025 Results on August 1, 2024

Nextracker to Present at the KeyBanc Capital Markets Technology Leadership Forum

Copeland Appoints New Chief Financial Officer

Nextracker Reports Q1 FY25 Financial Results

Nextracker Unveils NX Foundation Solutions Enabling Solar "Anywhere"

Comments

NEXTracker

空売り

NEXTracker (NASDAQ:NXT) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル